A new landscape for systemic pharmacotherapy ...
Type de document :
Article dans une revue scientifique: Éditorial
DOI :
PMID :
URL permanente :
Titre :
A new landscape for systemic pharmacotherapy of recurrent glioblastoma?
Auteur(s) :
Lombardi, Giuseppe [Auteur]
Veneto Institute of Oncology IOV-IRCCS [Padua, Italy]
Idbaih, Ahmed [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Le Rhun, Emilie [Auteur]
146992|||Universität Zürich [Zürich] = University of Zurich [UZH]
Preusser, Matthias [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Zagonel, Vittorina [Auteur]
Veneto Institute of Oncology IOV-IRCCS [Padua, Italy]
French, Pim [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Veneto Institute of Oncology IOV-IRCCS [Padua, Italy]
Idbaih, Ahmed [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Le Rhun, Emilie [Auteur]
146992|||Universität Zürich [Zürich] = University of Zurich [UZH]
Preusser, Matthias [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Zagonel, Vittorina [Auteur]
Veneto Institute of Oncology IOV-IRCCS [Padua, Italy]
French, Pim [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Titre de la revue :
Cancers
Nom court de la revue :
Cancers (Basel)
Numéro :
12
Pagination :
3775
Éditeur :
MDPI
Date de publication :
2020-12-15
ISSN :
2072-6694
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Glioblastoma is the most common and aggressive primary malignant brain tumor in adult patients. Despite multimodal treatment with maximal safe surgical resection followed by concurrent radiochemotherapy and adjuvant ...
Lire la suite >Glioblastoma is the most common and aggressive primary malignant brain tumor in adult patients. Despite multimodal treatment with maximal safe surgical resection followed by concurrent radiochemotherapy and adjuvant chemotherapy with temozolomide, the prognosis remains poor with a median survival of 1 year. The survival rate at 5 years is 5% and, theoretically, all glioblastomas relapse [1]. Once tumors progress, treatment options are limited, and the management of recurrent glioblastoma remains challenging. The standard of care for second-line treatment has not been defined; options include surgery, re-irradiation, systemic pharmacotherapy, and, in Europe, mostly lomustine [2,3]. The general and neurological health status of the patient, the molecular findings, the time to first recurrence, the pattern of recurrence, and previous treatment have to be considered. Nitrosoureas or temozolomide rechallenge show limited efficacy. Anti-vascular endothelial growth factor (VEGF) bevacizumab prolonged progression-free survival (PFS), but did not improve overall survival (OS) [4]. Because the treatment of recurrent glioblastoma remains a highly unmet clinical need, deeper mechanistic insight into the molecular changes present in these tumors is required. The enrollment of recurrent glioblastoma patients in clinical trials investigating new therapeutic options should be considered carefully whenever possible. In this Special Issue, we present some of the exciting updates on recurrent glioblastomas, which may help shape future treatment options.Lire moins >
Lire la suite >Glioblastoma is the most common and aggressive primary malignant brain tumor in adult patients. Despite multimodal treatment with maximal safe surgical resection followed by concurrent radiochemotherapy and adjuvant chemotherapy with temozolomide, the prognosis remains poor with a median survival of 1 year. The survival rate at 5 years is 5% and, theoretically, all glioblastomas relapse [1]. Once tumors progress, treatment options are limited, and the management of recurrent glioblastoma remains challenging. The standard of care for second-line treatment has not been defined; options include surgery, re-irradiation, systemic pharmacotherapy, and, in Europe, mostly lomustine [2,3]. The general and neurological health status of the patient, the molecular findings, the time to first recurrence, the pattern of recurrence, and previous treatment have to be considered. Nitrosoureas or temozolomide rechallenge show limited efficacy. Anti-vascular endothelial growth factor (VEGF) bevacizumab prolonged progression-free survival (PFS), but did not improve overall survival (OS) [4]. Because the treatment of recurrent glioblastoma remains a highly unmet clinical need, deeper mechanistic insight into the molecular changes present in these tumors is required. The enrollment of recurrent glioblastoma patients in clinical trials investigating new therapeutic options should be considered carefully whenever possible. In this Special Issue, we present some of the exciting updates on recurrent glioblastomas, which may help shape future treatment options.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
INSERM
Université de Lille
Université de Lille
Collections :
Date de dépôt :
2022-06-15T13:57:26Z
2023-03-01T08:40:05Z
2023-04-21T10:18:10Z
2023-03-01T08:40:05Z
2023-04-21T10:18:10Z
Fichiers
- cancers-12-03775-v3.pdf
- Non spécifié
- Accès libre
- Accéder au document